Characterization of seed nuclei in glucagon aggregation using light scattering methods and field-flow fractionation

被引：8
作者：
Hoppe C.C. [1 ]
Nguyen L.T. [2 ]
Kirsch L.E. [2 ]
Wiencek J.M. [3 ]
机构：
[1] Department of Chemical and Biochemical Engineering, University of Iowa, Iowa City
[2] Division of Pharmaceutics, University of Iowa, Iowa City
[3] Department of Chemical Engineering, University of South Florida, Tampa
来源：
Journal of Biological Engineering | / 2卷 / 1期
关键词：
Glucagon; Dynamic Light Scattering; Static Light Scattering; Molar Mass Distribution; Dynamic Light Scattering Result;
D O I：
10.1186/1754-1611-2-10
中图分类号：
学科分类号：
摘要：
Background: Glucagon is a peptide hormone with many uses as a therapeutic agent, including the emergency treatment of hypoglycemia. Physical instability of glucagon in solution leads to problems with the manufacture, formulation, and delivery of this pharmaceutical product. Glucagon has been shown to aggregate and form fibrils and gels in vitro. Small oligomeric precursors serve to initiate and nucleate the aggregation process. In this study, these initial aggregates, or seed nuclei, are characterized in bulk solution using light scattering methods and field-flow fractionation. Results: High molecular weight aggregates of glucagon were detected in otherwise monomeric solutions using light scattering techniques. These aggregates were detected upon initial mixing of glucagon powder in dilute HCl and NaOH. In the pharmaceutically relevant case of acidic glucagon, the removal of aggregates by filtration significantly slowed the aggregation process. Field-flow fractionation was used to separate aggregates from monomeric glucagon and determine relative mass. The molar mass of the large aggregates was shown to grow appreciably over time as the glucagon solutions gelled. Conclusion: The results of this study indicate that initial glucagon solutions are predominantly monomeric, but contain small quantities of large aggregates. These results suggest that the initial aggregates are seed nuclei, or intermediates which catalyze the aggregation process, even at low concentrations. © 2008 Hoppe et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 28 条
[1]  
Kim D.Y., Shin N.K., Chang S.G., Shin H.C., Production of recombinant human glucagon in Escherichia coli by a novel fusion protein approach, Biotechnology Techniques, 10, 9, pp. 669-672, (1996)
[2]  
Beaven G.H., Gratzer W.B., Davies H.G., Formation and structure of gels and fibrils from glucagon, Eur J Biochem, 11, pp. 37-42, (1969)
[3]  
Costantino H.R., Langer R., Klibanov A.M., Solid-phase aggregation of proteins under pharmaceutically relevant conditions, J Pharm Sci, 83, 12, pp. 1662-1669, (1994)
[4]  
Stefani M., Protein misfolding and aggregation: New examples in medicine and biology of the dark side of the protein world, Biochim Biophys Acta, 1739, 1, pp. 5-25, (2004)
[5]  
Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J.S., Taddei N., Ramponi G., Dobson C.M., Stefani M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases, Nature, 416, 6880, pp. 507-511, (2002)
[6]  
Kirkitadze M.D., Bitan G., Teplow D.B., Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies, J Neurosci Res, 69, 5, pp. 567-577, (2002)
[7]  
Stefani M., Dobson C.M., Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution, J Mol Med, 81, 11, pp. 678-699, (2003)
[8]  
Koo E.H., Lansbury P.T., Kelly J.W., Amyloid diseases: Abnormal protein aggregation in neurodegeneration, Proc Natl Acad Sci USA, 96, 18, pp. 9989-9990, (1999)
[9]  
De Jong K.L., Incledon B., Yip C.M., DeFelippis M.R., Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy, Biophys J, 91, 5, pp. 1905-1914, (2006)
[10]  
Dong M.D., Hovgaard M.B., Xu S.L., Otzen D.E., Besenbacher F., AFM study of glucagon fibrillation via oligomeric structures resulting in interwoven fibrils, Nanotechnology, 17, 16, pp. 4003-4009, (2006)
123